Personalized cancer therapy: Yes1 is the new kid on the block

Kunal Rai

doi:10.1158/0008-5472.CAN-19-2995

Personalized cancer therapy: Yes1 is the new kid on the block

Kunal Rai

Genomic Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The key bottleneck for the continued success of precision medicine in cancer lies in identifying more targetable genes and associated efficacious clinically usable inhibitors. In this issue of Cancer Research, Hamanaka and colleagues identify YES1 kinase as a targetable cancer target and generate an effective chemical inhibitor for YES1 and demonstrate its efficacy in YES1-amplified tumors.

Original language	English (US)
Pages (from-to)	5702-5703
Number of pages	2
Journal	Cancer Research
Volume	79
Issue number	22
DOIs	https://doi.org/10.1158/0008-5472.CAN-19-2995
State	Published - 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/0008-5472.CAN-19-2995

Cite this

@article{d4d14b180fd647a3b92392d0a08d925b,

title = "Personalized cancer therapy: Yes1 is the new kid on the block",

abstract = "The key bottleneck for the continued success of precision medicine in cancer lies in identifying more targetable genes and associated efficacious clinically usable inhibitors. In this issue of Cancer Research, Hamanaka and colleagues identify YES1 kinase as a targetable cancer target and generate an effective chemical inhibitor for YES1 and demonstrate its efficacy in YES1-amplified tumors.",

author = "Kunal Rai",

note = "Publisher Copyright: {\textcopyright}2019 American Association for Cancer Research.",

year = "2019",

doi = "10.1158/0008-5472.CAN-19-2995",

language = "English (US)",

volume = "79",

pages = "5702--5703",

journal = "Cancer Research",

issn = "0008-5472",

number = "22",

}

TY - JOUR

T1 - Personalized cancer therapy

T2 - Yes1 is the new kid on the block

AU - Rai, Kunal

PY - 2019

Y1 - 2019

N2 - The key bottleneck for the continued success of precision medicine in cancer lies in identifying more targetable genes and associated efficacious clinically usable inhibitors. In this issue of Cancer Research, Hamanaka and colleagues identify YES1 kinase as a targetable cancer target and generate an effective chemical inhibitor for YES1 and demonstrate its efficacy in YES1-amplified tumors.

AB - The key bottleneck for the continued success of precision medicine in cancer lies in identifying more targetable genes and associated efficacious clinically usable inhibitors. In this issue of Cancer Research, Hamanaka and colleagues identify YES1 kinase as a targetable cancer target and generate an effective chemical inhibitor for YES1 and demonstrate its efficacy in YES1-amplified tumors.

UR - http://www.scopus.com/inward/record.url?scp=85075066707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075066707&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-19-2995

DO - 10.1158/0008-5472.CAN-19-2995

M3 - Article

C2 - 31772072

AN - SCOPUS:85075066707

SN - 0008-5472

VL - 79

SP - 5702

EP - 5703

JO - Cancer Research

JF - Cancer Research

IS - 22

ER -

Personalized cancer therapy: Yes1 is the new kid on the block

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this